Blog
RSS FeedPosted by Michael Wonder on 13 Jun 2018
Janssen’s Tremfya (guselkumab) receives its first two positive Health Technology Assessments in Europe
13 June 2018 - The United Kingdom’s NICE publishes positive guidance for the first selective interleukin 23 inhibitor to treat moderate ...
Posted by Michael Wonder on 21 Mar 2018
Using real world data in health technology assessment (HTA) practice: a comparative study of five HTA agencies
21 March 2018 - This study examines whether real world data is incorporated in health technology assessment (HTA) of melanoma drugs ...